Shandong Xinhua Pharmaceutical (719) Stock Overview
Develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People’s Republic of China, the Americas, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
719 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shandong Xinhua Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.97 |
| 52 Week High | HK$9.46 |
| 52 Week Low | HK$5.11 |
| Beta | -0.12 |
| 1 Month Change | -2.65% |
| 3 Month Change | -16.53% |
| 1 Year Change | 13.89% |
| 3 Year Change | 76.01% |
| 5 Year Change | 84.39% |
| Change since IPO | 241.92% |
Recent News & Updates
Why Shandong Xinhua Pharmaceutical's (HKG:719) Shaky Earnings Are Just The Beginning Of Its Problems
Sep 05
Shandong Xinhua Pharmaceutical Company Limited's (HKG:719) 30% Price Boost Is Out Of Tune With Earnings
Jul 14Recent updates
Why Shandong Xinhua Pharmaceutical's (HKG:719) Shaky Earnings Are Just The Beginning Of Its Problems
Sep 05Shandong Xinhua Pharmaceutical Company Limited's (HKG:719) 30% Price Boost Is Out Of Tune With Earnings
Jul 14Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
May 17Shandong Xinhua Pharmaceutical (HKG:719) Has A Pretty Healthy Balance Sheet
Jan 14Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Shareholder Returns
| 719 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -5.8% | -2.0% | 2.3% |
| 1Y | 13.9% | 47.2% | 31.5% |
Return vs Industry: 719 underperformed the Hong Kong Pharmaceuticals industry which returned 47.2% over the past year.
Return vs Market: 719 underperformed the Hong Kong Market which returned 31.5% over the past year.
Price Volatility
| 719 volatility | |
|---|---|
| 719 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 719 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 719's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 7,159 | Wenhui Xu | www.xhzy.com |
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People’s Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials.
Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary
| 719 fundamental statistics | |
|---|---|
| Market cap | HK$9.98b |
| Earnings (TTM) | HK$418.15m |
| Revenue (TTM) | HK$9.29b |
Is 719 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 719 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.49b |
| Cost of Revenue | CN¥6.80b |
| Gross Profit | CN¥1.70b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥382.16m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 20.01% |
| Net Profit Margin | 4.50% |
| Debt/Equity Ratio | 28.2% |
How did 719 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 15:47 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ming Li | Industrial Securities Co. Ltd. |
| Laurence Tam | Morgan Stanley |
| Guohe Fan | Phillip Securities (HK) |